RAFAEL
RUBIO GARCÍA
Profesor titular de universidad
![Foto de RAFAEL](/img/uploaded/6CA654DD031F6FEF08160B3A8AA5CC20.jpg)
![Foto de GlaxoSmithKline (United Kingdom)](/img/noimage_org.png)
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublicacións en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (2)
2020
-
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials
Journal of acquired immune deficiency syndromes (1999), Vol. 85, Núm. 3, pp. 325-330
2002
-
Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy
Antiviral Therapy, Vol. 7, Núm. 1, pp. 43-51